A clinical trial to study the safety and tolerability of prophylactic Emicizumab in Hemophilia A patients.

Phase 3

• Conditions: Health Condition 1: null- Hemophilia A patients with inhibitorsHealth Condition 2: D66- Hereditary factor VIII deficiency

• Registration Number: CTRI/2018/03/012421
• Lead Sponsor: F HoffmannLa Roche Ltd

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 24 November 2021

Recruitment & Eligibility

• Status: Open to Recruitment
• Sex: Not specified
• Target Recruitment: 0

Inclusion Criteria

1. Signed Informed Consent Form

2. Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures, including the PRO questionnaires and bleed diaries through the use of an electronic device, as per the investigatorâ??s judgment

3. Aged 12 years or older at the time of informed consent

4. Body weight >=40 kg at the time of screening

5. Diagnosis of congenital hemophilia A with persistent inhibitors against FVIII

6. Adequate hematologic function

7. Adequate hepatic function

8. Adequate renal function

Exclusion Criteria

1. Inherited or acquired bleeding disorder other than hemophilia A

2. Ongoing (or plan to receive during the study) ITI therapy (prophylaxis regimens with FVIII and/or bypassing agents must be discontinued prior to enrollment).

3. History of illicit drug or alcohol abuse within 12 months prior to screening, as per the investigatorâ??s judgment

4. Other conditions (e.g., certain autoimmune diseases) that may increase the risk of bleeding or thrombosis

5. History of clinically significant hypersensitivity reaction associated with monoclonal antibody therapies

6. Known human immunodeficiency virus (HIV) infection

7. Concurrent disease, treatment, or abnormality in clinical laboratory tests that could interfere with the conduct of the study or that would, in the opinion of the investigator or Sponsor, preclude the patientâ??s safe participation in and completion of the study or interpretation of the study results

Study & Design

• Study Type: Interventional
• Study Design: Not specified